ENTRY       D10024                      Drug
NAME        Selumetinib sulfate (JAN/USAN);
            Koselugo (TN)
PRODUCT     KOSELUGO (AstraZeneca Pharmaceuticals LP)
FORMULA     C17H15BrClFN4O3. H2SO4
EXACT_MASS  553.9674
MOL_WEIGHT  555.7599
CLASS       Antineoplastic
             DG03137  MEK inhibitor
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG01642  CYP2C9 substrate
             DG01639  CYP2C19 substrate
             DG02855  CYP2E1 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
             DG02924  UGT substrate
              DG03183  UGT1A1 substrate
              DG03184  UGT1A3 substrate
REMARK      Therapeutic category: 4299
            ATC code: L01EE04
            Chemical structure group: DG01414
            Product (DG01414): D10024<JP/US>
EFFICACY    Antineoplastic, Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor
  DISEASE   Neurofibromatosis type 1 [DS:H01437]
TARGET      MAP2K1 (MEK1) [HSA:5604] [KO:K04368]
            MAP2K2 (MEK2) [HSA:5605] [KO:K04369]
  PATHWAY   hsa04010(5604+5605)  MAPK signaling pathway
            hsa04014(5604+5605)  Ras signaling pathway
METABOLISM  Enzyme: CYP3A4 [HSA:1576], UGT1A1 [HSA:54658], UGT1A3 [HSA:54659]; CYP2C19 [HSA:1557], CYP1A2 [HSA:1544], CYP2C9 [HSA:1559], CYP2E1 [HSA:1571], CYP3A5 [HSA:1577]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EE Mitogen-activated protein kinase (MEK) inhibitors
                 L01EE04 Selumetinib
                  D10024  Selumetinib sulfate (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Selumetinib
                D10024  Selumetinib sulfate (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4299  Others
                 D10024  Selumetinib sulfate (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG03137  MEK inhibitor
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
              DG01642  CYP2C9 substrate
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
              DG01639  CYP2C19 substrate
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
              DG02855  CYP2E1 substrate
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01414  Selumetinib
                 D10024  Selumetinib sulfate
              DG02925  CYP3A5 substrate
               DG01414  Selumetinib
                D10024  Selumetinib sulfate
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG01414  Selumetinib
                 D10024  Selumetinib sulfate
               DG03184  UGT1A3 substrate
                DG01414  Selumetinib
                 D10024  Selumetinib sulfate
            Drug classes [BR:br08332]
             Antineoplastic
              DG03137  MEK inhibitor
               D10024  Selumetinib sulfate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Serine/threonine kinases
               STE group
                MAP2K1 (MEK1)
                 D10024  Selumetinib sulfate (JAN/USAN) &lt;JP/US&gt;
                MAP2K2 (MEK2)
                 D10024  Selumetinib sulfate (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10024
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10024
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10024
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10024
            Drug groups [BR:br08330]
             Antineoplastic
              DG03137  MEK inhibitor
               DG01414  Selumetinib
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG01414  Selumetinib
              DG01642  CYP2C9 substrate
               DG01414  Selumetinib
              DG01639  CYP2C19 substrate
               DG01414  Selumetinib
              DG02855  CYP2E1 substrate
               DG01414  Selumetinib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01414  Selumetinib
              DG02925  CYP3A5 substrate
               DG01414  Selumetinib
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG01414  Selumetinib
               DG03184  UGT1A3 substrate
                DG01414  Selumetinib
DBLINKS     CAS: 943332-08-9
            PubChem: 135626745
            LigandBox: D10024
ATOM        32
            1   C8y C    28.8400  -21.4900
            2   C8y C    28.8400  -22.8900
            3   C8x C    27.6500  -23.5900
            4   C8y C    26.3900  -22.8900
            5   C8y C    26.3900  -21.4900
            6   C8y C    27.6500  -20.7900
            7   N5x N    30.1700  -21.0700
            8   C8x C    31.0100  -22.1900
            9   N4y N    30.1700  -23.3800
            10  X   F    27.6500  -19.3900
            11  N1b N    25.2000  -20.7900
            12  C5a C    25.2000  -23.6600
            13  N1b N    23.9400  -22.9600
            14  O5a O    25.2000  -25.0600
            15  O2a O    22.8200  -23.5900
            16  C1b C    21.5600  -22.9600
            17  C8y C    25.2000  -19.3900
            18  C8y C    24.0100  -18.6900
            19  C8x C    24.0100  -17.2900
            20  C8y C    25.2000  -16.5900
            21  C8x C    26.3900  -17.2900
            22  C8x C    26.3900  -18.6900
            23  X   Br   25.2000  -15.1900
            24  X   Cl   22.7500  -19.3900
            25  C1a C    30.5900  -24.7100
            26  C1b C    20.3700  -23.5900
            27  O1a O    19.1800  -22.9600
            28  S4a S    33.3900  -18.0600
            29  O1d O    33.3900  -16.6600
            30  O1d O    33.3900  -19.4600
            31  O1d O    34.7900  -18.0600
            32  O1d O    31.9900  -18.0600
BOND        33
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 2
            9     8   9 1
            10    2   9 1
            11    6  10 1
            12    5  11 1
            13    4  12 1
            14   12  13 1
            15   12  14 2
            16   13  15 1
            17   15  16 1
            18   11  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 2
            22   20  21 1
            23   21  22 2
            24   17  22 1
            25   20  23 1
            26   18  24 1
            27    9  25 1
            28   16  26 1
            29   26  27 1
            30   28  29 2
            31   28  30 2
            32   28  31 1
            33   28  32 1
///
